Loading
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Regular session
$98.885
−$2.855 · -2.81%
Regular session · ET · Market data may be delayed.
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Day range
Current $98.885
52-week range
Current $98.885
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
53
Fair Value
Sentiment
65
Bullish
Risk
56
Elevated Risk
Momentum
37
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Day range
Current $98.885
52-week range
Current $98.885
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 606.42M USD | 363.71M USD | 305.21M USD | 245.36M USD | 188.46M USD |
| Cost of goods sold | 124.88M USD | 85.74M USD | 65.57M USD | 55.13M USD | 44.15M USD |
| Gross profit | 481.55M USD | 277.97M USD | 239.64M USD | 190.23M USD | 144.31M USD |
| Research and development | 771.09M USD | 598.37M USD | 571.01M USD | 397.52M USD | 272.74M USD |
| Selling, general, and administrative | 701.17M USD | 461.12M USD | 344.5M USD | 265.78M USD | 234.27M USD |
| Operating expenses | 1.66B USD | 1.16B USD | 949.26M USD | 647.55M USD | 519.4M USD |
| Interest income | 60.66M USD | 53.31M USD | 42.13M USD | 11.08M USD | 174K USD |
| Interest expense | 83.8M USD | 84.91M USD | 81.69M USD | 26.45M USD | 40.47M USD |
| Depreciation and amortization | 16.45M USD | 11.01M USD | 10.58M USD | 10.33M USD | 14.18M USD |
| Operating income | −1.18B USD | −878.25M USD | −709.63M USD | −457.32M USD | −375.09M USD |
| Net income | −1.28B USD | −913.77M USD | −749.57M USD | −481.53M USD | −434.65M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI839.59M0.04%2.3T USD0.03%$378.79-0.59%
Vanguard Extended Market ETFVXF306.79M0.32%95.4B USD0.05%$232.43-0.45%
Vanguard Morningstar Small-Cap ETFVB303.8M0.16%185.3B USD0.03%$286.51-0.16%
Vanguard Morningstar Mid-Cap ETFVO285.57M0.13%226.4B USD0.03%$80.135-0.01%
Vanguard Morningstar Growth ETFVUG217.88M0.06%384.6B USD0.03%$91.27-1.24%
Vanguard Morningstar Small-Cap Growth ETFVBK174.36M0.38%44.7B USD0.05%$339.07-0.93%
iShares Biotechnology ETFIBB165.57M1.59%10.4B USD0.44%$199.31-1.98%
iShares Russell Mid-Cap Growth ETFIWP123M0.62%20.14B USD0.23%$140.39-0.76%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Mid-Cap ETFVOVanguard Morningstar Growth ETFVUGVanguard Morningstar Small-Cap Growth ETFVBKiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
